CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing - MyChesCo
KING OF PRUSSIA, PA — Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) yesterday presented results from the pivotal placebo-controlled Phase 3 VANGUARD clinical trial of garadacimab (CSL312). Garadacimab is …
MyChesCo
